Hikal Ltd announced significant leadership transitions following its Board meeting on October 1, 2026. Jai Hiremath ceased his role as Executive Chairman, while Anish Swadi was appointed as the new CEO for the Animal Health and Specialty Ingredients division.

The Board took note of the cessation of Mr. Hiremath's term as Executive Chairman with effect from October 1, 2026. Mr. Hiremath is the founder of the company and has led its strategic direction for nearly four decades. To acknowledge his contributions, the Board conferred upon him the honorary position of Chairman Emeritus for a period of five years. In this capacity, he will not serve as a Director, officer, or Key Managerial Personnel but will provide counsel on strategic matters.

Leadership Changes and Appointments

Mrs. Sugandha Hiremath resigned from her position as Non-Executive Director with effect from the close of business hours on September 30, 2026. Her resignation was attributed to personal commitments and other preoccupations. She had been associated with the company as a Director since 1992 and served on the Audit, Stakeholders' Relationship, and Corporate Social Responsibility Committees.

Based on the recommendations of the Nomination and Remuneration Committee, the Board approved the appointment of Mr. Anish Swadi as CEO-Animal Health and Specialty Ingredients, a Senior Management Position, effective October 1, 2026. Mr. Swadi has been associated with the company as Senior President – Business Transformation & Animal Health since October 1, 2021. He holds a degree in international business and finance from Ithaca College, New York.

Governance Transition Details

The changes reflect a structured transition in governance roles while retaining institutional memory through the Chairman Emeritus designation. The specific details of these regulatory disclosures are outlined below:

The Board meeting commenced at 11:30 am and concluded at 1:12 pm. The company filed these disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Hikal Limited shareholders approved the appointment of Sameer Hiremath as Chairman and Managing Director for a five-year term starting October 1, 2026. The decision was taken during the company's 38th Annual General Meeting held on September 23, 2026.

The meeting also ratified a total dividend of ₹0.60 per equity share for FY26. The appointment of Hiremath, effective from October 1, 2026, to September 30, 2031, received majority support despite institutional reservations. Shareholders also approved audited standalone and consolidated financial statements for the year ended March 31, 2026, along with the re-appointment of Sarangan Suresh as Executive Director.

Leadership continuity and remuneration

Sameer Hiremath has been associated with Hikal's Board since May 1999 and was last reappointed as Managing Director at the 2021 Annual General Meeting. His continued leadership spans almost three decades, during which Hikal expanded capabilities across pharmaceuticals, crop protection, and emerging life-sciences businesses.

Shareholders approved the revision in remuneration for Sarangan Suresh, Whole-Time Director, who was re-appointed following retirement by rotation. Additionally, the ratification of remuneration payable to Cost Auditors for FY27 was approved.

Voting results breakdown

The voting data reveals distinct patterns in shareholder support. While institutional investors showed strong alignment on financial matters, promoter group votes were split on several governance-related items.

What the numbers show

A significant divergence exists between promoter and public voting behavior regarding leadership appointments. For the appointment of Sameer Hiremath as CMD, promoters voted nearly evenly (50.59% in favour vs 49.40% against), while public institutions voted predominantly against (56.58% against). In contrast, non-institutional public shareholders voted overwhelmingly in favour (90.69%). This suggests that while retail investors supported the leadership continuity, institutional investors expressed reservations regarding the specific terms or appointment, which was narrowly overcome by the combined weight of promoter and retail votes.

Strategic expansion and sustainability

Hikal recently commenced commercial production of Personal Care products at its new cGMP-compliant multipurpose facility at Panoli, Gujarat. This facility marks Hikal's entry into commercial-scale manufacturing for the global beauty and personal care industry. The company also announced it has been awarded the EcoVadis Gold Medal rating, placing it among the top 5% of companies assessed globally for sustainability performance.